Morocco medicine price database

HUMIRA 40MG

ADALIMUMAB

Reimbursement base

12.195,00 MAD

Active substance

ADALIMUMAB

What is this medicine?

HADLIMA (adalimumab-bwwd) is a biosimilar to HUMIRA (adalimumab) that acts as a tumor necrosis factor (TNF) blocker.

Verified summary

ADALIMUMAB, SOLUTION INJECTABLE, 40 MG, 1 BOITE 2 SERINGUE PREREMPLIE

Common uses

moderately to severely active rheumatoid arthritis,moderately to severely active polyarticular juvenile idiopathic arthritis,active psoriatic arthritis,active ankylosing spondylitis,moderately to severely active Crohn’s disease,moderately to severely active ulcerative colitis,moderate to severe chronic plaque psoriasis,moderate to severe hidradenitis suppurativa,non-infectious intermediate, posterior, and panuveitis

Class

tumor necrosis factor (TNF) blocker

Hospital price

12.195,00 MAD

Strength

40 MG

Form

SOLUTION INJECTABLE

Presentation

1 BOITE 2 SERINGUE PREREMPLIE

Type

P

This information is informational and must be confirmed by a pharmacist or doctor. Do not change medicine or dosage based only on this page.

Price history

Reference price recorded since 2017-12-18: 0,00 MAD

Available presentations and strengths

Medicines with the same active substance